Equities Analysts Set Expectations for NAMS FY2026 Earnings

NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for NewAmsterdam Pharma in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the company will post earnings of ($2.25) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $42.00 target price on the stock. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is ($1.75) per share.

Other analysts have also issued research reports about the stock. Scotiabank upped their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 27th. Needham & Company LLC restated a "buy" rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday. Stifel Nicolaus initiated coverage on shares of NewAmsterdam Pharma in a report on Tuesday. They issued a "buy" rating and a $44.00 price target on the stock. UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a research note on Monday, March 3rd. Finally, Wall Street Zen upgraded NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research report on Friday, May 30th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.00.

NewAmsterdam Pharma Trading Down 3.9%

Shares of NewAmsterdam Pharma stock traded down $0.82 on Tuesday, reaching $20.21. The stock had a trading volume of 550,120 shares, compared to its average volume of 679,365. The business's 50 day moving average is $18.19 and its two-hundred day moving average is $20.86. NewAmsterdam Pharma has a 1 year low of $14.06 and a 1 year high of $27.29. The company has a market cap of $2.27 billion, a P/E ratio of -10.75 and a beta of -0.03.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The business had revenue of $2.98 million during the quarter, compared to analyst estimates of $1.46 million.

Insider Activity

In other news, Director James N. Topper acquired 1,135 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average cost of $22.49 per share, for a total transaction of $25,526.15. Following the transaction, the director now owns 3,013,569 shares of the company's stock, valued at $67,775,166.81. This trade represents a 0.04% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 20.84% of the company's stock.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds have recently bought and sold shares of the company. Quarry LP purchased a new position in shares of NewAmsterdam Pharma during the first quarter worth approximately $25,000. GF Fund Management CO. LTD. purchased a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at $50,000. National Bank of Canada FI bought a new position in shares of NewAmsterdam Pharma during the 4th quarter valued at $51,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in NewAmsterdam Pharma in the 4th quarter worth $80,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in NewAmsterdam Pharma by 130.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock worth $123,000 after purchasing an additional 3,390 shares during the last quarter. Institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.